Project description:We performed a targeted NGS using the commercial gene panel design ClearSeq Inherited Disease (Agilent Technologies) to identify the pathogenic sequence variants in children with ID/DD, ASD and MCA and their unaffected parents
Project description:The Investigators will conduct a longitudinal, mixed-methods cohort study to assess primary and secondary psychosocial outcomes among 705 MyCode pediatric participants and their parents, and health behaviors of parents whose children receive an adult- or pediatric-onset genomic result. Data will be gathered via quantitative surveys using validated measures of distress, family functioning, quality of life, body image, perceived cancer/heart disease risk, genetic counseling satisfaction, genomics knowledge, and adjustment to genetic information; qualitative interviews with adolescents and parents; and electronic health records review of parents’ cascade testing uptake and initiation of risk reduction behaviors. The investigators will also conduct empirical and theoretical legal research to examine the loss of chance doctrine and its applicability to genomic research.
Project description:A comparative panoramic mass spectrometric analysis of serum samples from three families with children with autistic disorders was carried out. The total number of examined samples was nine, including four control samples from healthy parents, and five samples from autistic children.
Project description:The cause of mental retardation in one-third to one-half of all affected individuals is unknown. Microscopically-detectable chromosomal abnormalities are the most frequent recognized cause, but gain or loss of chromosomal segments that are too small to be seen by conventional cytogenetic analysis has been found to be another important cause. Array-based methods offer a practical means of performing a high-resolution survey of the entire genome for submicroscopic copy number variants. We studied 100 children with idiopathic mental retardation and their parents using the Affymetrix GeneChip® Mapping 100K Assay and found de novo duplications as small as 1.1 Mb in three cases, de novo deletions as small as 178 kb in eight cases, and unsuspected mosaic trisomy 9 in another case. This technology can detect at least twice as many potentially pathogenic de novo copy number variants as conventional cytogenetic analysis in people with mental retardation. Experiment Overall Design: Using the Affymetrix GeneChip® Mapping 100K Assay we studied 100 trios that each included one child with idiopathic mental retardation (MR) and both of his/her unaffected biological parents. We also tested 10 unaffected siblings of the MR children from 10 of the above families. In addition, we analyzed 7 trios (child and both unaffected biological parents) as positive controls with previously identified chromosomal aberrations. Experiment Overall Design: Within each sample ID the four digit number refers to a family. Following this four digit family number, 'c' indicates child with MR, 'm' means unaffected mother, 'f' means unaffected father and 's' means unaffected sibling.
Project description:We designed a microarray to test at exonic resolution for genomic imbalance for genes representative of all known chromosomal microdeletion/microduplication syndromes, all known causative genes for ID, all known genes encoding glutamate receptors and their known encoding proteins and all known genes encoding proteins with epigenetic regulatory function. We found 36 de novo copy number variants affecting 35 children in this study. 167 trios, each comprising an affected child and both its normal parents were analyzed by conducting two comparative hybridizations; child vs. mother and child vs. father, and only selecting a CNV if it appeared in both hybridizations, i.e., was de novo. De novo CNVs were independantly validated using quantitative PCR.
Project description:Transgenerational effects of continuous low dose-rate (LDR) gamma-ray irradiation have not been well studied. C57BL/6JNrs male mice were maintained in non-irradiated room for 400 days from 8 weeks of age. This study investigated the De novo mutation by comparing the parents and children. This is secondary screening. This study was performed under contract with the Aomori Prefectural Government, Japan.
Project description:Transgenerational effects of continuous low dose-rate (LDR) gamma-ray irradiation have not been well studied. C57BL/6JNrs male mice were maintained in non-irradiated room for 400 days from 8 weeks of age. This study investigated the De novo mutation by comparing the parents and children. This is secondary screening. This study was performed under contract with the Aomori Prefectural Government, Japan.
Project description:Transgenerational effects of continuous low dose-rate (LDR) gamma-ray irradiation have not been well studied. C57BL/6JNrs male mice were maintained in non-irradiated room for 400 days from 8 weeks of age. This study investigated the De novo mutation by comparing the parents and children. This is secondary screening. This study was performed under contract with the Aomori Prefectural Government, Japan.
Project description:Transgenerational effects of continuous low dose-rate (LDR) gamma-ray irradiation have not been well studied. C57BL/6JNrs male mice were maintained in non-irradiated room for 400 days from 8 weeks of age. This study investigated the De novo mutation by comparing the parents and children. This is primary screening. This study was performed under contract with the Aomori Prefectural Government, Japan.
Project description:Transgenerational effects of continuous low dose-rate (LDR) gamma-ray irradiation have not been well studied. C57BL/6JNrs male mice were maintained in non-irradiated room for 400 days from 8 weeks of age. This study investigated the De novo mutation by comparing the parents and children. This is secondary screening. This study was performed under contract with the Aomori Prefectural Government, Japan.